Literature DB >> 23890678

Seroepidemiology of dengue in travellers: a paired sera analysis.

Karin Leder1, Margot Mutsch, Patricia Schlagenhauf, Christine Luxemburger, Joseph Torresi.   

Abstract

BACKGROUND: Dengue is a frequent cause of fever in travellers. The true extent is unknown as many infections are asymptomatic or undiagnosed.
METHODS: We used paired sera, with pre- and post-travel specimens from Swiss travellers to tropical destinations, to evaluate the seroepidemiology of travel-related dengue. Post-travel specimens were tested for the presence of IgG and IgM antibodies to dengue antigen serotypes (1, 2, 3 and 4) using an indirect enzyme-linked immunosorbent assay (ELISA). All post-travel sera that screened as positive for dengue IgG or IgM antibodies were re-tested with the corresponding pre-travel sera as paired assays in order to detect seroconversion.
RESULTS: There were 285 travellers with specimens available for analysis. Two hundred and fifty seven of the 285 individuals (90.2%) had negative dengue serology post-travel. Of the remaining 28 cases, 25 were dengue IgG positive and 3 had equivocal results. This corresponds to IgG seropositivity in 8.9%. Eighteen of these 25 individuals had a pre-travel specimen available for testing, of which 15 were positive for IgG consistent with possible past exposure. Three of the 18 had negative serology pre-travel, indicating possible recent infection. This corresponds to an attack rate of possible dengue of 1.1% and an incidence rate of 6.7 per 1000 person-months (95% CI 0-60.0). Two of these three individuals had received yellow fever vaccine for their trip, raising the potential of cross-reactivity. The confirmed dengue attack rate therefore was 0.23% with a corresponding incidence rate of 2.2 per 1000 person-months (95% CI-0-33.1).
CONCLUSIONS: Seroepidemiology provides additional evidence of an appreciable risk of acute dengue infection among travellers to tropical destinations.
Copyright © 2013. Published by Elsevier Ltd.

Entities:  

Keywords:  Dengue; ELISA; Seroepidemiology; Traveller

Mesh:

Substances:

Year:  2013        PMID: 23890678     DOI: 10.1016/j.tmaid.2013.06.008

Source DB:  PubMed          Journal:  Travel Med Infect Dis        ISSN: 1477-8939            Impact factor:   6.211


  5 in total

Review 1.  Vaccines licensed and in clinical trials for the prevention of dengue.

Authors:  J Torresi; G Ebert; M Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

2.  Dengue Virus Seroconversion in Travelers to Dengue-Endemic Areas.

Authors:  Rosemary M Olivero; Davidson H Hamer; William B MacLeod; Christine M Benoit; Carolina Sanchez-Vegas; Emily S Jentes; Lin H Chen; Mary E Wilson; Nina Marano; Emad A Yanni; Winnie W Ooi; Adolf W Karchmer; Laura Kogelman; Elizabeth D Barnett
Journal:  Am J Trop Med Hyg       Date:  2016-08-29       Impact factor: 2.345

3.  Seroprevalence of Dengue Virus, West Nile Virus, Chikungunya Virus, and Zika Virus in International Travelers Attending a Travel and Migration Center in 2015-2017, Southern Italy.

Authors:  Daniela Loconsole; Angela Metallo; Anna Lisa De Robertis; Anna Morea; Michele Quarto; Maria Chironna
Journal:  Vector Borne Zoonotic Dis       Date:  2018-04-23       Impact factor: 2.133

4.  Dengue Underestimation in Guangzhou, China: Evidence of Seroprevalence in Communities With No Reported Cases Before a Large Outbreak in 2014.

Authors:  Qinlong Jing; Yilan Li; Jianhua Liu; Liyun Jiang; Zongqiu Chen; Wenzhe Su; Guthrie S Birkhead; Jiahai Lu; Zhicong Yang
Journal:  Open Forum Infect Dis       Date:  2019-06-03       Impact factor: 3.835

5.  Dengue virus infection among long-term travelers from the Netherlands: A prospective study, 2008-2011.

Authors:  Femke W Overbosch; Janke Schinkel; Ineke G Stolte; Maria Prins; Gerard J B Sonder
Journal:  PLoS One       Date:  2018-02-07       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.